18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China
IntroductionEarly stable deep molecular response (DMR) to nilotinib is associated with goal of treatment-free remission (TFR) in patients with chronic-phase chronic myeloid leukemia (CML-CP). It is important to early distinguish between patients who can achieve a DMR and those who are fit for TFR.Me...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1267512/full |
| _version_ | 1827761430645964800 |
|---|---|
| author | Bingbing Wen Yuming Zhang Haiqing Lin Jin Lou Chuangqing Tu Yirong Jiang Xiaolian Liu Yan Chen Huiqing He Zelin Liu Xiaoling Xie Wangxiang Huang Liping Pang Xin Du |
| author_facet | Bingbing Wen Yuming Zhang Haiqing Lin Jin Lou Chuangqing Tu Yirong Jiang Xiaolian Liu Yan Chen Huiqing He Zelin Liu Xiaoling Xie Wangxiang Huang Liping Pang Xin Du |
| author_sort | Bingbing Wen |
| collection | DOAJ |
| description | IntroductionEarly stable deep molecular response (DMR) to nilotinib is associated with goal of treatment-free remission (TFR) in patients with chronic-phase chronic myeloid leukemia (CML-CP). It is important to early distinguish between patients who can achieve a DMR and those who are fit for TFR.MethodsWe performed a multicenter study to explore the early cumulative MR4.5 rate at 18 months with nilotinib in patients with newly diagnosed CML-CP (ND-CML-CP) in China. Of the 29 institutes, 106 patients with ND-CML-CP received nilotinib (300 mg BID).Results and discussionThe cumulative MR4.5 rate of nilotinib treatment at 18 months was 69.8% (74/106). The cumulative MMR and MR4.0 rates for nilotinib at 18 months were 94.3% (100/106) and 84.9% (90/106), respectively. Patients with an ultra-early molecular response (u-EMR) at 6 weeks were not significantly different in obtaining DMR or MMR by 24 months compared with those without u-EMR (p = 0.7584 and p = 0.9543, respectively). Our study demonstrated that nilotinib treatment in patients with ND-CML-CP contributed to obtain high early MR4.5. |
| first_indexed | 2024-03-11T10:12:49Z |
| format | Article |
| id | doaj.art-6ae310d4fea543838cc22acbbeae2818 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-11T10:12:49Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-6ae310d4fea543838cc22acbbeae28182023-11-16T14:20:24ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-11-011010.3389/fmed.2023.1267512126751218 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in ChinaBingbing Wen0Yuming Zhang1Haiqing Lin2Jin Lou3Chuangqing Tu4Yirong Jiang5Xiaolian Liu6Yan Chen7Huiqing He8Zelin Liu9Xiaoling Xie10Wangxiang Huang11Liping Pang12Xin Du13Department of Hematology, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, ChinaDepartment of Hematology, Affiliated General Hospital of Guangdong Medical University, Zhanjiang, ChinaDepartment of Hematology, Shenzhen People's Hospital, Shenzhen, ChinaDepartment of Hematology, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, ChinaDepartment of Hematology, Shenzhen Baoan People's Hospital, Shenzhen, ChinaDepartment of Hematology, Dongguan People's Hospital, Dongguan, ChinaDepartment of Hematology, Gaozhou People Hospital, Gaozhou, ChinaDepartment of Hematology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, ChinaDepartment of Hematology, Zhongshan City People's Hospital, Zhongshan, ChinaDepartment of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, China0Department of Hematology, Huizhou Municipal Central Hospital, Huizhou, China1Department of Hematology, Shenzhen Longgang Central Hospital, Shenzhen, China2Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, ChinaDepartment of Hematology, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, ChinaIntroductionEarly stable deep molecular response (DMR) to nilotinib is associated with goal of treatment-free remission (TFR) in patients with chronic-phase chronic myeloid leukemia (CML-CP). It is important to early distinguish between patients who can achieve a DMR and those who are fit for TFR.MethodsWe performed a multicenter study to explore the early cumulative MR4.5 rate at 18 months with nilotinib in patients with newly diagnosed CML-CP (ND-CML-CP) in China. Of the 29 institutes, 106 patients with ND-CML-CP received nilotinib (300 mg BID).Results and discussionThe cumulative MR4.5 rate of nilotinib treatment at 18 months was 69.8% (74/106). The cumulative MMR and MR4.0 rates for nilotinib at 18 months were 94.3% (100/106) and 84.9% (90/106), respectively. Patients with an ultra-early molecular response (u-EMR) at 6 weeks were not significantly different in obtaining DMR or MMR by 24 months compared with those without u-EMR (p = 0.7584 and p = 0.9543, respectively). Our study demonstrated that nilotinib treatment in patients with ND-CML-CP contributed to obtain high early MR4.5.https://www.frontiersin.org/articles/10.3389/fmed.2023.1267512/full18 monthsdeep molecular responsenilotinibnewly diagnosedchronic-phase chronic myeloid leukemia |
| spellingShingle | Bingbing Wen Yuming Zhang Haiqing Lin Jin Lou Chuangqing Tu Yirong Jiang Xiaolian Liu Yan Chen Huiqing He Zelin Liu Xiaoling Xie Wangxiang Huang Liping Pang Xin Du 18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China Frontiers in Medicine 18 months deep molecular response nilotinib newly diagnosed chronic-phase chronic myeloid leukemia |
| title | 18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China |
| title_full | 18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China |
| title_fullStr | 18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China |
| title_full_unstemmed | 18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China |
| title_short | 18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China |
| title_sort | 18 months follow up of deep molecular response 4 5 mr4 5 with nilotinib in patients with newly diagnosed chronic phase chronic myeloid leukemia a prospective multi center study in china |
| topic | 18 months deep molecular response nilotinib newly diagnosed chronic-phase chronic myeloid leukemia |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1267512/full |
| work_keys_str_mv | AT bingbingwen 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT yumingzhang 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT haiqinglin 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT jinlou 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT chuangqingtu 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT yirongjiang 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT xiaolianliu 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT yanchen 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT huiqinghe 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT zelinliu 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT xiaolingxie 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT wangxianghuang 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT lipingpang 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina AT xindu 18monthsfollowupofdeepmolecularresponse45mr45withnilotinibinpatientswithnewlydiagnosedchronicphasechronicmyeloidleukemiaaprospectivemulticenterstudyinchina |